When analyzing the studies regarding methodological quality we found three flaws: small sample size (of quantitative studies); a lack of nesting effects; and inadequately controlling for experience for early writing.
Reverse-phase protein array (RPPA) technology has emerged as a robust, sensitive, cost-effective approach to the analysis of large numbers of samples for quantitative assessment of key members of functional pathways that are affected by tumor-targeting therapeutics.
In terms of age, gender, multi-morbidity and poly-pharmacy, the sample of the quantitative component was comparable to the overall German nursing home population [ 27, 28].
Discrepancies in quality assessment between reviewers related primarily to how findings related to researchers' influence and sampling strategy of quantitative data, and were settled through consensus.
However, our theoretically informed and rigorous mixed methods approach, integrating a comprehensive sampling of qualitative and quantitative data, strengthens the empirical basis of the model.
In the analysis of post-dose biological samples for quantitative determination of two analytes that can potentially undergo interconversion, it is essential to minimize the interconversion during the multiple steps of the bioanalytical method.
Three biological samples in duplicate of quantitative PCR experiments were performed for each sample as described in García-Rojas et al. [ 57].
That is, given an out-of-sample quantitative outcome vector (y2) and its prediction (y ^ 2 ), the accuracy measure should be such that for any coefficient b > 0 the accuracy of prediction y ^ 2 is identical to that of prediction y ^ 2 ∗ = b y ^ 2.
To meet the need to compare the abundance of proteins in different samples, a number of quantitative approaches have been developed.
Therefore, it is of paramount importance that future confirmatory studies include use of independent ILC and IDC samples for quantitative expression profiling of the selected candidate genes.
